Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPAIR: Baricitinib vs Sarilumab for Methotrexate-Resistant Rheumatoid Arthritis Joint Pain
jRCT1031230107Recruiting
- Start
- Jun 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial in rheumatoid arthritis (RA) comparing Baricitinib arm with Sarilumab arm (2 arms). Primary endpoint: ACR20 response rate at 12 weeks. Started Jun 2023; status: recruiting.
02
Drugs
baricitinibsarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT1031230107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230107.